


## PHARMACEUTICAL 2022

## Eledon Pharmaceuticals Inc. Rank 100 of 475





## PHARMACEUTICAL 2022



## Eledon Pharmaceuticals Inc. Rank 100 of 475

The relative strengths and weaknesses of Eledon Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Eledon Pharmaceuticals Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 57% points. The greatest weakness of Eledon Pharmaceuticals Inc. is the variable Revenues, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 46%, being 322% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	88,346
Cost of Goods Sold	0
Intangible Assets	48,648
Liabilities, Current	4,401
Liabilities, Non-Current	400
Other Assets	33,554
Other Compr. Net Income	0
Other Expenses	-2,354
Other Liabilities	1,752
Other Net Income	7.0
Property and Equipment	0
Research and Development	23,735
Revenues	0
Selling, General and Administrative Expense	13,132

Output Variable	Value in 1000 USD
Assets	170,548
Liabilities	6,553
Expenses	34,513
Stockholders Equity	163,995
Net Income	-34,506
Comprehensive Net Income	-34,506
Economic Capital Ratio	46%